Search

Your search keyword '"Denkert, C."' showing total 1,126 results

Search Constraints

Start Over You searched for: Author "Denkert, C." Remove constraint Author: "Denkert, C."
1,126 results on '"Denkert, C."'

Search Results

2. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

4. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

5. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

6. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

8. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

11. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

15. Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆

16. Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)

17. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo

20. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration

21. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study

22. Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto

32. 99P Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with HER2-positive residual invasive breast cancer after neoadjuvant treatment (NAT)

33. 208P Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases: A subanalysis of the German brain metastases in breast cancer registry (BMBC)

34. 129P Impact of TROP-2 and its cellular localization on prognosis of breast cancer in the GAIN cohort

35. 167P Deep learning-based whole slide image analysis to predict sentinel node status in the INSEMA cohort

36. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study

38. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

39. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial

42. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer – The Phase III NeoAdjuvant Trial Add-oN (NaTaN) study (GBG 36/ABCSG 29)

45. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

48. Long-term survival of HER2-positive breast cancer patients with brain metastases: subanalysis of the BMBC Registry

Catalog

Books, media, physical & digital resources